SAVA Logo

Cassava Sciences, Inc. (SAVA) 

NASDAQ
Market Cap
$1.27B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
704 of 775
Rank in Industry
389 of 433

Largest Insider Buys in Sector

SAVA Stock Price History Chart

SAVA Stock Performance

About Cassava Sciences, Inc.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, …

Insider Activity of Cassava Sciences, Inc.

Over the last 12 months, insiders at Cassava Sciences, Inc. have bought $0 and sold $0 worth of Cassava Sciences, Inc. stock.

On average, over the past 5 years, insiders at Cassava Sciences, Inc. have bought $3.28M and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 30,000 shares for transaction amount of $523,500 was made by ROBERTSON SANFORD (director) on 2023‑08‑23.

List of Insider Buy and Sell Transactions, Cassava Sciences, Inc.

2023-08-23Purchasedirector
30,000
0.0716%
$17.45$523,500+23.16%
2023-08-22Purchasedirector
16,571
0.0382%
$16.65$275,907+24.23%
2023-08-21Purchasedirector
1,906
0.0046%
$16.80$32,021+27.38%
2023-03-07Purchasedirector
77,276
0.1893%
$25.76$1.99M-9.92%
2023-03-06Purchasedirector
11,565
0.0275%
$26.13$302,193-13.62%
2022-08-23Purchase
36,159
0.0849%
$23.79$860,223+3.97%
2022-08-23PurchaseChief Clinical Dev. Officer
2,500
0.006%
$24.44$61,100+3.97%
2022-08-12Purchase
100,000
0.253%
$20.69$2.07M+29.04%
2022-08-12PurchaseChief Financial Officer
2,500
0.0061%
$19.95$49,875+29.04%
2020-09-24PurchasePresident and CEO
10,000
0.0395%
$9.59$95,900+369.31%
2020-09-18Purchasedirector
36,281
0.1287%
$8.92$323,627+341.71%
2020-09-17Purchasedirector
213,719
0.8426%
$6.98$1.49M+527.36%
2020-09-17PurchaseChief Financial Officer
12,000
0.0477%
$7.03$84,380+527.36%
2019-12-31PurchasePresident and CEO
100,000
0.4344%
$5.53$553,000+31.73%
2019-12-26PurchasePresident and CEO
10,000
0.0567%
$4.15$41,500+65.01%
2019-12-20Purchasedirector
423,788
2.2827%
$2.20$932,334+172.00%
2019-12-19Purchasedirector
76,212
0.411%
$1.86$141,754+222.11%
2019-12-19PurchaseChief Financial Officer
5,300
0.0289%
$1.88$9,964+222.11%
2019-12-18PurchasePresident and CEO
2,599
0.0141%
$1.65$4,288+264.29%
2019-05-14PurchaseChief Financial Officer
10,000
0.0583%
$1.06$10,600+31.13%

Insider Historical Profitability

20.28%
BLACK BEAR OFFSHORE MASTER FUND LP10 percent owner
5810453
12.0773%
$26.42719+9.41%
EASTBOURNE CAPITAL MANAGEMENT LLC/CA10 percent owner
3230204
6.7141%
$26.421017<0.0001%
BARBIER REMIPresident and CEO
1078855
2.2425%
$26.426112+182.87%
ROBERTSON SANFORDdirector
886851
1.8434%
$26.42140+109.58%
Barry Richarddirector
293477
0.61%
$26.4250<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$61.79M6.353.05M+0.27%+$163,314.21<0.01
The Vanguard Group$47.81M4.912.36M+1.37%+$646,317.66<0.01
State Street$22.19M2.281.09M+2.23%+$483,490.42<0.01
Geode Capital Management$18.3M1.88901,840+3.19%+$565,030.69<0.01
Gallacher Capital Management Llc$11.88M1.22585,381+0.65%+$76,594.726.39
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.